New Zealand approves party-drug MDMA for treating patients with PTSD

New Zealand Grants Formal Approval for MDMA-Assisted Therapy in Treating Severe Post-Traumatic Stress Disorder

Two New Zealand psychiatrists have won the right to prescribe pharmaceutical-grade MDMA to patients with severe post-traumatic stress disorder (PTSD), marking the country as the second in the world—after Australia in 2023—to authorize the formerly illegal party drug for clinical use.

ADVERTISEMENT
ADVERTISEMENT

[{“class”:”c-ad__placeholder__logo”,”src”:”https://static.euronews.com/website/images/logos/logo-euronews-stacked-outlined-72×72-grey-9.svg”,”width”:”72″,”height”:”72″,”alt”:””,”loading”:”lazy”},{“text”:”ADVERTISEMENT”}]

The New Zealand medicines regulator, Medsafe, granted these authorizations to Wellington-based Dr. Gary Wynn and Auckland-based Dr. Tom Paterson after completing more than a year of rigorous regulatory review.

“PTSD devastates lives and presents significant therapeutic challenges,” stated Deputy Prime Minister David Seymour, whose recent backing of psilocybin research highlights the nation’s forward-thinking approach.

“MDMA shows substantial potential for relieving symptoms via guided psychedelic‑assisted therapy,” he added, emphasizing New Zealand’s commitment to expanding access to innovative treatments.

Post‑traumatic stress disorder arises following exposure—or imminent threat of—traumatic events including combat, sexual assault, or Sudden Death.

Currently, pharmaceutical options available in most nations are restricted to two antidepressants, which typically require three months to demonstrate efficacy and often yield inconsistent outcomes.

The evidence behind the approval — and why the US said no

This authorization is based on data from two landmark international Phase 3 trials conducted by the US‑based Multidisciplinary Association for Psychedelic Studies (MAPS) and sponsored by its public benefit arm Lykos Therapeutics.

The initial study, published in 2021, revealed that 88 % of participants with severe PTSD undergoing MDMA‑assisted therapy achieved clinically significant improvement, with 67 % no longer meeting diagnostic criteria for PTSD.

A subsequent trial in 2023, involving individuals with moderate‑to‑severe PTSD, determined that 71.2 % of those treated achieved symptom remission by the study’s conclusion.

Despite these positive results, the US Food and Drug Administration declined authorization in 2024, arguing that sufficient evidence was lacking to confirm safety and effectiveness.

Regulators expressed concern that previous MDMA users exhibited expectancy bias, which complicated the interpretability of trial data.

New Zealand’s Ministry of Health clarified that the new treatment protocol utilizes tightly controlled administration combined with psychotherapy within a clinical setting rather than take‑home doses. Therapy must occur under the supervision of an authorized psychiatrist as part of a comprehensive care plan, and patients must be aged 18 or older.

[{“class”:”c-ad__placeholder__logo”,”src”:”https://static.euronews.com/website/images/logos/logo-euronews-stacked-outlined-72×72-grey-9.svg”,”width”:”72″,”height”:”72″,”alt”:””,”loading”:”lazy”}}]

Source link